MedTrace Logo

Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy

NCT05678881 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2024-05-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate RLS103 for safety and suppression of the epileptic photoparoxysmal response compared to placebo.

Conditions

Interventions

DRUG

High dose RLS103

8 mg CBD inhaled powder

DRUG

placebo inhaled powder

placebo inhaled powder

DRUG

Low dose RLS103

4 mg CBD inhaled powder (open label)

Sponsors & Collaborators

  • The Epilepsy Study Consortium

    collaborator OTHER

  • Receptor Life Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-25
Primary Completion
2024-02-23
Completion
2024-02-23
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05678881 on ClinicalTrials.gov